Article Information
History
- January 18, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Paul E. Hanna, MD MSc1,*,
- Qiyu Wang, MD1,*,
- Ian Strohbehn, BA1,
- Daiana Moreno, BS1,
- Destiny Harden, BA1,
- Tianqi Ouyang, MPH1,
- Nurit Katz-Agranov, MD1,
- Harish Seethapathy, MBBS1,
- Kerry L. Reynolds, MD2,
- Shruti Gupta, MD MPH3,4,
- David E. Leaf, MD MMSc3 and
- Meghan E. Sise, MD MS1,†
- 1Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, MA
- 2Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA
- 3Division of Renal Medicine, Brigham and Women’s Hospital, Boston, MA
- 4Adult Survivorship Program, Dana-Farber Cancer Institute, Boston, MA
- ↵†Corresponding Author: Meghan Sise, MD, MS, 165 Cambridge St. Suite 302, Boston, MA 02108, msise{at}partners.org, 617-726-5050
↵* Equal contribution
Posted January 18, 2023.
Medication-related adverse events in patients with cancer and discrepancies in cystatin C- versus creatinine-based eGFR
